FAS and lip and oral cavity carcinoma: Shen et al demonstrated that low-dose, metronomic chemotherapy with Cis (0.6 mg/kg/day) dramatically inhibits tumor growth without apparent body weight loss and significant upregulation of Fas (CD95) mRNA and protein in SW480 colon cancer cells and oral cancer cell lines.